Micro Cap Growth Fund
Daily price w/o sales charge as of 05/13/2026
$29.92
$0.17
YTD Returns w/o sales charge as of 05/13/2026
23.69%
Please click here for performance current to the most recent quarter-end and month-end.
Summary
Summary
Fund Basicsas of 04/30/2026
- Total Net Assets
- $203.62 M
- Inception Date
- 08/28/2020
- Dividend Frequency
- Annually
- Fund Gross Expense Ratio
- 1.22%
- Fund Net Expense Ratio
- 1.12%
- Number of Holdings
- 79
Fund Expense Ratio :
Gross 1.22%
Net 1.12%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 08/01/2010 |
|---|
| w/o sales charge | 16.16% | 52.47% | 18.07% | 2.40% | 17.70% | 11.85% |
| Lipper Category Avg. Small-Cap Growth Funds | 9.59% | 33.98% | 14.80% | 2.56% | 11.53% | - |
| Russell Microcap® Growth Index | 10.15% | 59.08% | 21.56% | 1.78% | 9.61% | - |
| w/ sales charge | 16.16% | 52.47% | 18.07% | 2.40% | 17.70% | 11.85% |
Fund Expense Ratio :
Gross 1.22%
Net 1.12%
Fund Expense Ratio :
Gross 1.22%
Net 1.12%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 08/01/2010 |
|---|
| w/o sales charge | 0.25% | 35.47% | 12.48% | -0.32% | 16.22% | 11.27% |
| Lipper Category Avg. Small-Cap Growth Funds | -2.19% | 18.82% | 10.03% | 1.17% | 10.44% | - |
| Russell Microcap® Growth Index | -4.25% | 41.85% | 15.49% | -1.21% | 8.34% | - |
Fund Expense Ratio :
Gross 1.22%
Net 1.12%
Past performance is not a reliable indicator or guarantee of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost.
TEN LARGEST HOLDINGS as of 03/31/2026View Portfolio
| Holding | Assets |
|---|---|
| Cogent Biosciences Inc | 4.0% |
| Celcuity Inc | 3.1% |
| Tarsus Pharmaceuticals Inc | 2.7% |
| Cardinal Infrastructure Group Inc | 2.6% |
| Adaptive Biotechnologies Corp | 2.5% |
| Lincoln Educational Services Corp | 2.5% |
| Terns Pharmaceuticals Inc | 2.4% |
| Mirum Pharmaceuticals Inc | 2.4% |
| Terawulf Inc | 2.4% |
| Legence Corp | 2.3% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Sector Allocationas of 04/30/2026View Portfolio
| Sector | Weighting |
|---|
| Sector | Weighting |
|---|---|
| Communication Services | |
| Real Estate | |
| Utilities | |
| Consumer Discretionary | |
| Consumer Staples | |
| Energy | |
| Financials | |
| Health Care | |
| Industrials | |
| Information Technology | |
| Materials |
INVESTMENT TEAM
Your Representative
To contact your representative, enter your zip code and select your channel below.
Performance
Performance
Fund Expense Ratio :
Gross 1.22%
Net 1.12%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 08/01/2010 |
|---|
| w/o sales charge | 16.16% | 52.47% | 18.07% | 2.40% | 17.70% | 11.85% |
| Lipper Category Avg. Small-Cap Growth Funds | 9.59% | 33.98% | 14.80% | 2.56% | 11.53% | - |
| Russell Microcap® Growth Index | 10.15% | 59.08% | 21.56% | 1.78% | 9.61% | - |
| w/ sales charge | 16.16% | 52.47% | 18.07% | 2.40% | 17.70% | 11.85% |
Fund Expense Ratio :
Gross 1.22%
Net 1.12%
Fund Expense Ratio :
Gross 1.22%
Net 1.12%
| YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 08/01/2010 |
|---|
| w/o sales charge | 0.25% | 35.47% | 12.48% | -0.32% | 16.22% | 11.27% |
| Lipper Category Avg. Small-Cap Growth Funds | -2.19% | 18.82% | 10.03% | 1.17% | 10.44% | - |
| Russell Microcap® Growth Index | -4.25% | 41.85% | 15.49% | -1.21% | 8.34% | - |
Fund Expense Ratio :
Gross 1.22%
Net 1.12%
Past performance is not a reliable indicator or guarantee of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost.
| Year | Fund Returns | Russell Microcap® Growth Index |
|---|
| 2025 | 11.01% | 21.84% |
| 2024 | 27.28% | 21.91% |
| 2023 | 6.14% | 9.11% |
| 2022 | -29.10% | -29.76% |
| 2021 | 3.74% | 0.88% |
| 2020 | 79.62% | 40.13% |
| 2019 | 34.56% | 23.33% |
| 2018 | 2.85% | -14.18% |
| 2017 | 38.38% | 16.65% |
| 2016 | 2.05% | 6.86% |
| 2015 | -6.38% | - |
| 2014 | 10.84% | - |
| 2013 | 78.60% | - |
| 2012 | 2.61% | - |
| 2011 | -5.68% | - |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|
| 2026 | 0.25% | - | - | - |
| 2025 | -17.85% | 15.92% | 13.98% | 2.28% |
| 2024 | 7.71% | 0.22% | 6.93% | 10.27% |
| 2023 | 5.64% | 4.23% | -13.34% | 11.24% |
| 2022 | -17.19% | -22.51% | 8.29% | 2.02% |
| 2021 | 12.36% | -0.04% | -9.38% | 1.93% |
| 2020 | -24.27% | 47.66% | 17.49% | 36.72% |
| 2019 | 22.62% | 7.46% | -13.89% | 18.59% |
| 2018 | 5.33% | 15.78% | 10.04% | -23.35% |
| 2017 | 8.97% | 8.17% | 13.63% | 3.32% |
| 2016 | -13.66% | 5.93% | 14.56% | -2.61% |
| 2015 | 7.34% | 4.13% | -16.29% | 0.06% |
| 2014 | 7.88% | -6.49% | -6.59% | 17.62% |
| 2013 | 21.81% | 15.05% | 17.29% | 8.65% |
| 2012 | 17.75% | -9.67% | 1.33% | -4.80% |
| 2011 | 4.83% | 0.21% | -21.88% | 14.92% |
NAV Historical Prices
| Date | Net Asset Value |
|---|
Portfolio
Portfolio
| Holding | Sector | Assets |
|---|
| Cogent Biosciences Inc | Health Care | 4.0% |
| Celcuity Inc | Health Care | 3.1% |
| Tarsus Pharmaceuticals Inc | Health Care | 2.7% |
| Cardinal Infrastructure Group Inc | Industrials | 2.6% |
| Adaptive Biotechnologies Corp | Health Care | 2.5% |
| Lincoln Educational Services Corp | Consumer Discretionary | 2.5% |
| Terns Pharmaceuticals Inc | Health Care | 2.4% |
| Mirum Pharmaceuticals Inc | Health Care | 2.4% |
| Terawulf Inc | Information Technology | 2.4% |
| Legence Corp | Industrials | 2.3% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
| Holding | Sector | Assets |
|---|
| Cogent Biosciences Inc | Health Care | 4.0% |
| Celcuity Inc | Health Care | 3.1% |
| Tarsus Pharmaceuticals Inc | Health Care | 2.7% |
| Cardinal Infrastructure Group Inc | Industrials | 2.6% |
| Adaptive Biotechnologies Corp | Health Care | 2.5% |
| Lincoln Educational Services Corp | Consumer Discretionary | 2.5% |
| Terns Pharmaceuticals Inc | Health Care | 2.4% |
| Mirum Pharmaceuticals Inc | Health Care | 2.4% |
| Terawulf Inc | Information Technology | 2.4% |
| Legence Corp | Industrials | 2.3% |
| Sterling Infrastructure Inc | Industrials | 2.1% |
| Applied Digital Corp | Information Technology | 2.0% |
| CECO Environmental Corp | Industrials | 1.8% |
| Bel Fuse Inc | Information Technology | 1.8% |
| Universal Technical Institute Inc | Consumer Discretionary | 1.8% |
| Dianthus Therapeutics Inc | Health Care | 1.8% |
| OSI Systems Inc | Information Technology | 1.7% |
| Nektar Therapeutics | Health Care | 1.7% |
| Mercury Systems Inc | Industrials | 1.6% |
| Fastly Inc | Information Technology | 1.6% |
| VSE Corp | Industrials | 1.6% |
| PTC Therapeutics Inc | Health Care | 1.6% |
| Sphere Entertainment Co | Communication Services | 1.6% |
| Navan Inc | Consumer Discretionary | 1.5% |
| Vita Coco Co Inc/The | Consumer Staples | 1.5% |
| IMAX Corp | Communication Services | 1.5% |
| Praxis Precision Medicines Inc | Health Care | 1.5% |
| AAR Corp | Industrials | 1.5% |
| Lindblad Expeditions Holdings Inc | Consumer Discretionary | 1.5% |
| Piper Sandler Cos | Financials | 1.3% |
| BlackSky Technology Inc | Industrials | 1.3% |
| Mineralys Therapeutics Inc | Health Care | 1.3% |
| Miami International Holdings Inc | Financials | 1.2% |
| Argan Inc | Industrials | 1.2% |
| Standex International Corp | Industrials | 1.2% |
| Pattern Group Inc | Consumer Discretionary | 1.2% |
| 10X Genomics Inc | Health Care | 1.1% |
| ORIC Pharmaceuticals Inc | Health Care | 1.1% |
| Aehr Test Systems | Information Technology | 1.0% |
| StoneX Group Inc | Financials | 1.0% |
| Artivion Inc | Health Care | 1.0% |
| York Space Systems Inc | Industrials | 1.0% |
| Gilat Satellite Networks Ltd | Information Technology | 0.9% |
| Calix Inc | Information Technology | 0.9% |
| Willdan Group Inc | Industrials | 0.9% |
| Chefs' Warehouse Inc/The | Consumer Staples | 0.9% |
| nLight Inc | Information Technology | 0.9% |
| Rhythm Pharmaceuticals Inc | Health Care | 0.9% |
| Xometry Inc | Industrials | 0.8% |
| MYR Group Inc | Industrials | 0.8% |
| Mama's Creations Inc | Consumer Staples | 0.8% |
| HeartFlow Inc | Health Care | 0.8% |
| Neptune Insurance Holdings Inc | Financials | 0.8% |
| TransMedics Group Inc | Health Care | 0.8% |
| Transcat Inc | Industrials | 0.8% |
| Twist Bioscience Corp | Health Care | 0.7% |
| American Public Education Inc | Consumer Discretionary | 0.7% |
| Applied Optoelectronics Inc | Information Technology | 0.7% |
| Newamsterdam Pharma Co NV | Health Care | 0.7% |
| Ondas Inc | Information Technology | 0.7% |
| TAT Technologies Ltd | Industrials | 0.7% |
| Paymentus Holdings Inc | Financials | 0.7% |
| Ouster Inc | Information Technology | 0.7% |
| Warby Parker Inc | Consumer Discretionary | 0.6% |
| Ambarella Inc | Information Technology | 0.6% |
| Billiontoone Inc | Health Care | 0.6% |
| Marex Group PLC | Financials | 0.6% |
| Turning Point Brands Inc | Consumer Staples | 0.5% |
| Primoris Services Corp | Industrials | 0.5% |
| CG oncology Inc | Health Care | 0.5% |
| Hinge Health Inc | Health Care | 0.5% |
| Dave Inc | Financials | 0.5% |
| Immunocore Holdings PLC | Health Care | 0.5% |
| Forte Biosciences Inc | Health Care | 0.5% |
| Ceribell Inc | Health Care | 0.5% |
| Centrus Energy Corp | Energy | 0.4% |
| Neogen Corp | Health Care | 0.4% |
| GeneDx Holdings Corp | Health Care | 0.4% |
| Cipher Digital Inc | Information Technology | 0.4% |
| Zeta Global Holdings Corp | Information Technology | 0.4% |
| Red Violet Inc | Information Technology | 0.2% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Sector Allocationas of 04/30/2026
| Sector | Weighting | Fund Change from Previous Quarter |
|---|
| Sector | Weighting | Fund Change from Previous Quarter |
|---|---|---|
| Communication Services |
0.1%
|
|
| Real Estate | 0.0% | |
| Utilities | 0.0% | |
| Consumer Discretionary |
 1.2%
|
|
| Consumer Staples |
0.2%
|
|
| Energy |
0.4%
|
|
| Financials |
1.3%
|
|
| Health Care |
6.5%
|
|
| Industrials |
2.6%
|
|
| Information Technology |
4.0%
|
|
| Materials | 0.0% |
Portfolio Details as of 04/30/2026
- Total Net Assets
- $203.62 M
- Number of Holdings
- 79
- Weighted Average Market Cap.
- 4.6 B
- P/B Ratio
- 7.2x
- P/E Ratio
- 31.0x
To view definitions for the above Portfolio Details, Click here.
P/B Ratio - A ratio that helps determine whether a stock is undervalued or overvalued. It is calculated by dividing a stock's price per share by its book value per share. The result is based upon a weighted average of the securities held in the fund.
P/E Ratio - Is the weighted average of each holding's P/E ratio (price of a stock divided by its earnings per share). The result is based upon a weighted average of the securities held in the fund.
Weighted Average Market Cap - The average market capitalization of all companies held in the portfolio with each company weighted according to its percent held in the portfolio. The result is based upon a weighted average of the securities held in the fund.
Dividends & Cap Gains
Dividends & Cap Gains
Upcoming Dividend Payment Dates
This section lists all anticipated Income and Capital Gain distribution dates and any actual distributions are subject to adequacy of earnings and must be approved by the Board of Directors/Trustees. Please note that dates are subject to change.
| Record Date | Ex-Dividend Date | Reinvest & Payable Date |
|---|---|---|
| 11/23/2026 | 11/24/2026 | 11/24/2026 |
Capital Gains Distributions
| Record Date | Reinvest & Payable Date | Long-term | Short-term * | Total | Reinvest Price |
|---|---|---|---|---|---|
| 11/23/2020 | 11/24/2020 | $2.8043 | $2.2741 | $5.0784 | $18.90 |
Taxed as ordinary income
Lord Abbett does not provide tax advice. It is strongly recommended that you discuss the impact of dividends and distributions with your tax advisor.
Fees & Expenses
Fees & Expenses
Expense Ratioas of 04/30/2026
| Fund Gross Expense Ratio | 1.22% |
| Fund Net Expense Ratio | 1.12% |
Expense ratio details, Click here.
The net expense ratio for Class F takes into account a contractual fee waiver agreement currently scheduled to remain in place through 02/28/2027 of the Fund's 0.10% Rule 12b-1 fee. For periods when fees or expenses were waived and/or reimbursed, the share class benefited by not bearing such expenses. Without such waivers, performance would have been lower.
Fund Documents
Fund Documents
|
0Documents selected
|
||||
|---|---|---|---|---|
|
Portfolio Holdings 1Q
Publish Date:11/03/2015
|
||||
|
Portfolio Holdings 3Q
Publish Date:11/03/2015
|
||||
|
Summary Prospectus
Publish Date:11/03/2015
|
||||
|
Statutory Prospectus
Publish Date:11/03/2015
|
||||
|
SAI
Publish Date:11/03/2015
|
||||
|
Annual Financial Statements and Other Information *
Publish Date:11/03/2015
|
||||
|
2025 Annual Tailored Shareholder Report
Publish Date:11/03/2015
|
||||
|
2025 Semi-Annual Tailored Shareholder Report
Publish Date:11/03/2015
|
||||
|
Semi-Annual Financial Statements and Other Information *
Publish Date:11/03/2015
|
||||
|
Fact Sheet
Publish Date:11/03/2015
|